文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer.影像学在预测胃癌新辅助化疗反应中的作用。

World J Gastroenterol. 2014 Feb 21;20(7):1650-6. doi: 10.3748/wjg.v20.i7.1650.

2

Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy.胃癌新辅助化疗疗效评估的影像学进展。

Abdom Radiol (NY). 2023 Dec;48(12):3661-3676. doi: 10.1007/s00261-023-04046-1. Epub 2023 Oct 3.

3

[Present status of clinical trials of neoadjuvant chemotherapy for gastric cancer and key points in their design].[胃癌新辅助化疗的临床试验现状及其设计要点]

Zhonghua Zhong Liu Za Zhi. 2013 Aug;35(8):636-8.

4

[Efficacy of neoadjuvant chemotherpy in patients with locally advanced gastric cancer].新辅助化疗对局部晚期胃癌患者的疗效

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Feb;16(2):166-9.

5

Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.18F-FDG PET/CT 与弥散加权磁共振成像联合预测骨肉瘤新辅助化疗的组织学反应：初步结果。

J Nucl Med. 2013 Jul;54(7):1053-9. doi: 10.2967/jnumed.112.115964. Epub 2013 May 13.

6

Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.ERCC1、ERCC2和XRCC表达对接受新辅助mFOLFOX-4化疗的局部晚期或转移性胃癌患者的预测价值

Pathol Oncol Res. 2020 Apr;26(2):1105-1116. doi: 10.1007/s12253-019-00666-5. Epub 2019 May 10.

7

Neoadjuvant chemotherapy for gastric cancer. Has the time to decelerate the enthusiasm passed us by?胃癌的新辅助化疗。减速的时机是否已经错过？

Semin Oncol. 2020 Dec;47(6):355-360. doi: 10.1053/j.seminoncol.2020.07.003. Epub 2020 Jul 25.

8

FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.FDG-PET-CT 识别局部晚期胃癌和贲门癌新辅助化疗后的组织病理学无应答者：队列研究。

BMC Cancer. 2018 May 9;18(1):548. doi: 10.1186/s12885-018-4477-4.

9

[Preoperative chemotherapy of gastric cancer].[胃癌的术前化疗]

Vopr Onkol. 2010;56(2):226-33.

10

Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer.多模态放射组学模型预测局部晚期直肠癌新辅助化疗的治疗反应。

World J Gastroenterol. 2020 May 21;26(19):2388-2402. doi: 10.3748/wjg.v26.i19.2388.

引用本文的文献

1

Advanced Gastric Cancer: CT Radiomics Prediction of Lymph Modes Metastasis After Neoadjuvant Chemotherapy.进展期胃癌：新辅助化疗后淋巴结转移的CT影像组学预测

J Imaging Inform Med. 2024 Dec;37(6):2910-2919. doi: 10.1007/s10278-024-01148-0. Epub 2024 Jun 17.

2

HIST1H2BK predicts neoadjuvant-chemotherapy response and mediates 5-fluorouracil resistance of gastric cancer cells.HIST1H2BK可预测胃癌细胞对新辅助化疗的反应并介导其对5-氟尿嘧啶的耐药性。

Transl Oncol. 2024 Aug;46:102017. doi: 10.1016/j.tranon.2024.102017. Epub 2024 Jun 9.

3

Two-photon imaging reveals histopathological changes in the gastric tumor microenvironment induced by neoadjuvant treatment.双光子成像揭示了新辅助治疗诱导的胃肿瘤微环境中的组织病理学变化。

Biomed Opt Express. 2023 Sep 8;14(10):5085-5096. doi: 10.1364/BOE.501519. eCollection 2023 Oct 1.

4

Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer.TET1 介导的 DNA 羟甲基化上调 CRABP2 减轻胃癌中线粒体凋亡并促进奥沙利铂耐药性。

Cell Death Dis. 2022 Oct 4;13(10):848. doi: 10.1038/s41419-022-05299-2.

5

Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer).Delta放射组学与局部晚期胃癌新辅助治疗反应——意大利胃癌研究组（GIRCG）的多中心研究

Quant Imaging Med Surg. 2021 Jun;11(6):2376-2387. doi: 10.21037/qims-20-683.

6

Indications of neoadjuvant chemotherapy for locally advanced Gastric Cancer patients based on pre-treatment clinicalpathological and laboratory parameters.基于治疗前临床病理和实验室参数的局部晚期胃癌患者新辅助化疗指征

J Cancer. 2020 Aug 18;11(20):6000-6008. doi: 10.7150/jca.46430. eCollection 2020.

7

Imaging strategies in the management of gastric cancer: current role and future potential of MRI.胃癌管理中的成像策略：MRI的当前作用及未来潜力

Br J Radiol. 2019 May;92(1097):20181044. doi: 10.1259/bjr.20181044. Epub 2019 Mar 5.

8

ROS and the DNA damage response in cancer.活性氧（ROS）与癌症中的 DNA 损伤反应。

Redox Biol. 2019 Jul;25:101084. doi: 10.1016/j.redox.2018.101084. Epub 2018 Dec 21.

9

Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study.CT检查时胃癌最大肿瘤直径缩小率作为新辅助治疗后组织病理学退缩的影像学预测指标：一项多中心GIRCG研究

Gastroenterol Res Pract. 2018 Mar 15;2018:1794524. doi: 10.1155/2018/1794524. eCollection 2018.

10

An application study of low-dose computed tomography perfusion imaging for evaluation of the efficacy of neoadjuvant chemotherapy for advanced gastric adenocarcinoma.低剂量 CT 灌注成像在评估晚期胃腺癌新辅助化疗疗效中的应用研究。

Gastric Cancer. 2018 May;21(3):413-420. doi: 10.1007/s10120-017-0763-0. Epub 2017 Sep 4.

本文引用的文献

1

Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A).胃癌新辅助化疗疗效评估标准的有效性（JCOG0507-A）。

Gastric Cancer. 2014;17(3):514-21. doi: 10.1007/s10120-013-0294-2. Epub 2013 Sep 3.

2

Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis.胃癌新辅助治疗期间的内镜检查结果与组织病理学反应和预后相关。

Gastric Cancer. 2014;17(3):478-88. doi: 10.1007/s10120-013-0296-0. Epub 2013 Sep 1.

3

Expression of orphan nuclear receptor NR4A2 in gastric cancer cells confers chemoresistance and predicts an unfavorable postoperative survival of gastric cancer patients with chemotherapy.核受体 NR4A2 在胃癌细胞中的表达赋予了化疗耐药性，并预测了接受化疗的胃癌患者术后生存不良。

Cancer. 2013 Oct 1;119(19):3436-45. doi: 10.1002/cncr.28228. Epub 2013 Jul 2.

4

Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy.局部进展期胃癌新辅助化疗或放化疗的病理及肿瘤学结果。

Yonsei Med J. 2013 Jul;54(4):888-94. doi: 10.3349/ymj.2013.54.4.888.

5

Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.使用 18F-FDG 和 89Zr-曲妥珠单抗 PET 监测曲妥珠单抗治疗 HER2 阳性胃癌。

J Nucl Med. 2013 Jun;54(6):936-43. doi: 10.2967/jnumed.112.110239. Epub 2013 Apr 11.

6

Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy.对比增强超声造影评估胃癌新辅助化疗的反应。

World J Gastroenterol. 2012 Dec 21;18(47):7026-32. doi: 10.3748/wjg.v18.i47.7026.

7

Endoscopic ultrasound in restaging and predicting pathological response for advanced gastric cancer patients after neoadjuvant chemotherapy.内镜超声在晚期胃癌患者新辅助化疗后的再分期及预测病理反应中的应用

Asia Pac J Clin Oncol. 2014 Jun;10(2):e28-32. doi: 10.1111/ajco.12045. Epub 2012 Dec 21.

8

Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.代谢肿瘤体积和肿瘤总体糖酵解预测和预后价值在实体肿瘤中的应用。

Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):290-301. doi: 10.1007/s00259-012-2280-z. Epub 2012 Nov 14.

9

Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer.miRNA let-7i 表达降低及其与人胃癌化疗反应的关系。

World J Surg Oncol. 2012 Oct 29;10:225. doi: 10.1186/1477-7819-10-225.

10

Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery.新辅助化疗和手术治疗后，胃癌患者具有不同的预后结局，提出一种多因素预后评分系统，可将这 3 组患者准确分类。

Ann Surg. 2012 Dec;256(6):1002-7. doi: 10.1097/SLA.0b013e318262a591.

影像学在预测胃癌新辅助化疗反应中的作用。

Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer.

作者信息

Kwee Robert Michael, Kwee Thomas Christian

机构信息

Robert Michael Kwee, Department of Radiology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands.

出版信息

World J Gastroenterol. 2014 Feb 21;20(7):1650-6. doi: 10.3748/wjg.v20.i7.1650.

DOI:10.3748/wjg.v20.i7.1650

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3930965/

Abstract

With the proven overall benefit of neoadjuvant chemotherapy in patients with locally advanced gastric cancer, there has come a need to discriminate responders from non-responders. In this article, the current role of anatomical and molecular imaging in the prediction of response to neoadjuvant therapy in gastric cancer is outlined and future prospects are discussed.

摘要

鉴于新辅助化疗对局部晚期胃癌患者已证实的总体益处，区分反应者与无反应者变得很有必要。本文概述了解剖学和分子成像在预测胃癌新辅助治疗反应中的当前作用，并讨论了未来前景。